Skip to content

Study · Randomized controlled trial · n = 164 · 1991

5 results

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.

Soloway MS, Chodak G, Vogelzang NJ, Block NL, Schellhammer PF, Smith JA Jr, Scott M, Kennealey G, Gau TC

Urology1 Jan 1991Cited by 49 (Europe PMC)

PMID1824732 (opens in a new tab)DOI10.1016/0090-4295(91)80077-k (opens in a new tab)PepBankPUB-01824732
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Stage D2 prostate cancer, objective response occurred in 81 percent with goserelin versus 78 percent with orchiectomy.

    In plain wordsIn prostate cancer, objective response occurred in 81 percent with goserelin versus 78 percent with orchiectomy.

    Peptide
    Goserelin
    Outcome
    Not applicableObjective response
    Study

    n = 164

    Comparator
    Orchiectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mgAs given in this study (human).

    Measurements

    Objective response
    81%
    goserelin
    Objective response
    78%
    orchiectomy

    Source sentences

    Summary
    An objective response according to modified criteria of the National Prostatic Cancer Project was observed in 81 percent and 78 percent of patients in the Zoladex and orchiectomy groups, respectively.
    2 context sentences
    Summary · context
    We report preliminary results for the first 164 patients enrolled in a multicenter study comparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer.
    Summary · context
    Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Stage D2 prostate cancer, time to treatment failure did not significantly differ between goserelin and orchiectomy.

    In plain wordsIn prostate cancer, time to treatment failure did not significantly differ between goserelin and orchiectomy.

    Peptide
    Goserelin
    Outcome
    No significant changeTime to treatment failure
    Study

    n = 164

    Comparator
    Orchiectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mgAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences between treatment groups in the distributions of time to treatment failure or time to disease progression.
    2 context sentences
    Summary · context
    We report preliminary results for the first 164 patients enrolled in a multicenter study comparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer.
    Summary · context
    Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Stage D2 prostate cancer, time to disease progression did not significantly differ between goserelin and orchiectomy.

    In plain wordsIn prostate cancer, time to disease progression did not significantly differ between goserelin and orchiectomy.

    Peptide
    Goserelin
    Outcome
    No significant changeTime to disease progression
    Study

    n = 164

    Comparator
    Orchiectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mgAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences between treatment groups in the distributions of time to treatment failure or time to disease progression.
    2 context sentences
    Summary · context
    We report preliminary results for the first 164 patients enrolled in a multicenter study comparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer.
    Summary · context
    Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy.
  4. 04HumanNon-randomized trialActivity measurement

    In Stage D2 prostate cancer, goserelin and orchiectomy reduced testosterone to castrate levels within four weeks, with suppression up to sixty weeks.

    In plain wordsIn prostate cancer, goserelin and orchiectomy reduced testosterone to castrate levels within four weeks and maintained suppression up to sixty weeks.

    Peptide
    Goserelin
    Outcome
    DecreaseSerum testosterone suppression
    Study

    n = 164

    Comparator
    Orchiectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.6 mgAs given in this study (human).

    Measurements

    Testosterone
    < 50 ng/dL
    castrate level

    Source sentences

    Summary
    Median serum levels of testosterone were reduced to castrate levels (less than 50 ng/dL) within four weeks in both groups and remained suppressed for up to sixty weeks.
    2 context sentences
    Summary · context
    We report preliminary results for the first 164 patients enrolled in a multicenter study comparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer.
    Summary · context
    Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy.
  5. 05HumanNon-randomized trialSafety outcome

    In Stage D2 prostate cancer, common adverse events in both goserelin and orchiectomy groups included hot flashes, cancer-related pain, unspecified pain, and urinary symptoms.

    In plain wordsIn prostate cancer, both goserelin and orchiectomy groups commonly reported hot flashes, cancer-related pain, unspecified pain, and urinary symptoms.

    Peptide
    Goserelin
    Outcome
    Not applicableCommonly reported adverse events
    Study

    n = 164

    Comparator
    Orchiectomy
    Outcome group
    Adverse events · Cancer
    Studied dose
    3.6 mgAs given in this study (human).

    Source sentences

    Summary
    The most commonly reported adverse events in both treatment groups were hot flashes, cancer-related pain, unspecified pain, and urinary symptoms.
    2 context sentences
    Summary · context
    We report preliminary results for the first 164 patients enrolled in a multicenter study comparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer.
    Summary · context
    Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.